Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO opened at $0.28 on Friday. The company has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.39. Aptevo Therapeutics has a 1 year low of $0.14 and a 1 year high of $10.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.